Expression Level of Protein Kinase D in Oral Squamous Cell Carcinoma with Diverse Differentiation
目的 探索口腔鳞状细胞癌（oral squamous cell carcinoma, OSCC）组织中蛋白激酶D（protein kinase D, PKD）1、2、3的表达情况及其与口腔鳞癌分化程度的关系。 方法 收集10例正常口腔上皮组织、40例OSCC组织样本，采用免疫组化SP法检测PKD1、PKD2和PKD3的表达，评判阳性细胞比率及对染色强度进行评分，分析不同分化程度的OSCC组织中PKD1、PKD2和PKD3间的差异性，并分析PKD1、PKD2和PKD3免疫组化染色评分与OSCC分化程度的相关性。 结果 PKD1和PKD3在OSCC组织中高表达；不同分化程度的OSCC组织中，PKD1、PKD2及PKD3免疫组化染色评分间差异均有统计学意义（P<0.001）；PKD1和PKD2的免疫组化染色评分与OSCC分化程度呈负相关关系（r分别为−0.574和−0.341, P<0.001）。 结论 不同分化程度的OSCC组织中，起主导作用的PKDs可能存在差异；PKD1和PKD2的表达水平与OSCC的分化程度存在相关性，OSCC分化程度越低，PKD1及PKD2的表达越高。Abstract: Objective This study aimed to investigate the expression level of protein kinase D (PKD) in oral squamous cell carcinoma (OSCC) and its relationship with differentiation of OSCC. Methods Sample was collected from 10 healthy control subjects and 40 OSCC confirmed by histopathological diagnosis, and the immunohistochemical staining was adopted to detect the expression of PKDs in OSCC tissues. The proportion of stained cell and staining intensity were evaluated to get a score, which used to analyze the difference among PKD1, PKD2 and PKD3 in various differentiation OSCC tissues. The correlations between the staining score of PKDs and differentiation of OSCC were further analyzed. Results PKD1 and PKD3 were high expression in OSCC tissues. There were statistical significance among the staining score of PKD1, PKD2 and PKD3 in various differentiation OSCC tissues (P<0.001). In addition, there was a significantly negative correlation between the staining score of PKD1 and PKD2 with the differentiation of OSCC (r=−0.574, −0.341, P<0.001). Conclusion In OSCC tissues with different degree of differentiation, there might be some differences among PKDs which play a major role. The expression of PKD1 and PKD2 was correlated with the differentiation of OSCC, the poor differentiation of OSCC, the higher expression of PKD1 and PKD2.
表 1 PKD1、PKD2和PKD3在高分化、中分化及低分化OSCC组织中的免疫组化染色评分及其与OSCC分化程度的相关性
Table 1. The immumohistochemical (IHC) score of PKD1, PKD2 and PKD3 in well differentiated OSCC, moderately differentiated OSCC and poorly differentiated OSCC, and the correlation between the IHC score of PKDs with the differentiation of OSCC
Differentiation degree n PKD1 PKD2 PKD3 P IHC score r P IHC score r P IHC score r P Well differentiated 15 5.67±1.76 −0.574 <0.001 1.11±1.17 −0.341 <0.001 6.89±2.41 −0.073 0.389 <0.001 Moderately
Poorly differentiated 10 11.30±3.64* 3.00±1.94 7.63±3.32* <0.001 *P<0.001, vs. well differentiated.
 桂心伟, 姚小武, 陈仕生, 等. NF-κB在口腔鳞状细胞癌及癌旁组织中的表达意义. 口腔疾病防治,2019,27(6): 360–363.  TANG D, TAO D, FANG Y, et al. TNF-alpha promotes invasion and metastasis via NF-Kappa B pathway in oral squamous cell carcinoma. Med Sci Monit Basic Res,2017,23: 141–149. doi: 10.12659/MSMBR.903910  WANG P, LIU J, SONG Y, et al. Screening of immunosuppressive factors for biomarkers of breast cancer malignancy phenotypes and subtype-specific targeted therapy. Peer J,2019,7: e7197[2019-09-21].https://doi.org/10.7717/peerj.7197. doi: 10.7717/peerj.7197  WANG X, BAI Y, HAN Y, et al. Downregulation of GBAS regulates oral squamous cell carcinoma proliferation and apoptosis via the p53 signaling pathway. Onco Targets Ther,2019,12: 3729–3742. doi: 10.2147/OTT.S207930  ASHE S, YADAV S. Maintenance of rhodopsin levels in drosophila photoreceptor and phototransduction requires protein kinase D. Fly(Austin),2018,12(3/4): 164–173.  BORGES S, PEREZ E A, THOMPSON E A, et al. Effective targeting of estrogen receptor-negative breast cancers with the protein kinase D inhibitor CRT006610111306. Mol Cancer Ther,2015,14(6): 1306–1316. doi: 10.1158/1535-7163.MCT-14-0945  余宇, 卢婉鹭, 陈娇, 等. 蛋白激酶D1沉默可降低人涎腺腺样囊性癌细胞ACC-2对紫杉醇的敏感度. 肿瘤防治研究,2016,43(6): 448–452. doi: 10.3971/j.issn.1000-8578.2016.06.003  XU X H, JIN T. The novel functions of the PLC/PKC/PKD signaling axis in G protein-coupled receptor-mediated chemotaxis of neutrophils. J Immunol Res,2015,2015: 817604[2019-12-13]. https://doi.org/10.1155/2015/817604. doi: 10.1155/2015/817604  WANG Q J. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci,2006,27(6): 317–323. doi: 10.1016/j.tips.2006.04.003  BORGES S, DÖPPLER H, PEREZ E A, et al. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Res,2013,15(2): R66[2019-12-13]. https://doi.org/10.1186/bcr3460. doi: 10.1186/bcr3460  EISELER T, DÖPPLER H, YAN I K, et al. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res,2009,11(1): R13[2019-12-13]. https://doi.org/10.1186/bcr2232. doi: 10.1186/bcr2232  DURAND N, BORGES S, STORZ P. Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. Cell Mol Life Sci,2015,72(22): 4369–4382. doi: 10.1007/s00018-015-2011-2  SOLOMON B, YOUNG R J, RISCHIN D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol,2018,52: 228–240. doi: 10.1016/j.semcancer.2018.01.008  CHI A C, DAY T A, NEVILLE B W. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin,2015,65(5): 401–421. doi: 10.3322/caac.21293  RYKX A, DEKIMPE L, MIKHALAP S, et al. Protein kinase D: a family affair. FEBS Lett,2003,546(1): 81–86. doi: 10.1016/S0014-5793(03)00487-3  ISHIKAWA E, KOSAKO H, YASUDA T, et al. Protein kinase D regulates positive selection of CD4+ thymocytes through phosphorylation of SHP-1. Nat Commun, 2016, 7: 12756[2019-12-13]. https://doi.org/10.1038/ncomms12756.  OLAYIOYE M A, BARISIC S, HAUSSER A. Multi-level control of actin dynamics by protein kinase D. Cell Signal,2013,25(9): 1739–1747. doi: 10.1016/j.cellsig.2013.04.010  DöPPLER H, BASTEA L I, BORGES S, et al. Protein kinase D isoforms differentially modulate cofilin-driven directed cell migration. PLoS One, 2014, 9(5): e98090[2019-09-21]. https://doi.org/10.1371/journal.pone.0098090.  STARUSCHENKO A. To cleave or not to cleave: role of ADAM17 in cell proliferation in PKD. Am J Physiol Renal,2014,307(6): F658–F659. doi: 10.1152/ajprenal.00341.2014  EISLER S A, CURADO F, LINK G, et al. A Rho signaling network links microtubules to PKD controlled carrier transport to focal adhesions. eLife, 2018, 7: e35907[2019-09-21]. https://doi.org/10.7554/eLife.35907.001.  DURAND N, BORGES S, STORZ P. Protein kinase D enzymes as regulators of EMT and cancer cell invasion. J Clin Med,2016,5(2): 20[2019-09-21]. https://doi.org/10.3390/jcm5020020. doi: 10.3390/jcm5020020  XU W, QIAN J, ZENG F, et al. Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment. J Exp Clin Canc Res,2019,38(1): 114[2019-09-21]. https://doi.org/10.1186/s13046-019-1118-y. doi: 10.1186/s13046-019-1118-y  SUHA S, REY O, ROZENGURT E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res,2002,62(6): 1632–1640.  SHABELNIK M Y, KOVALEVSKA L M, YURCHENKO M Y, et al. Differential expression of PKD1 and PKD2 in gastric cancer and analysis of PKD1 and PKD2 function in the model system. Exp Oncol,2011,33(4): 206–211.  KIM M, JANG H R, KIM J H, et al. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis,2007,29(3): 629–637. doi: 10.1093/carcin/bgm291  CHEN J, DENG F, SINGH S V, et al. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKC/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res,2008,68(10): 3844–3853. doi: 10.1158/0008-5472.CAN-07-5156  TANDON M, JOHNSON J, LI Z, et al. New pyrazolopyrimidine inhibitors of protein kinase D as potent anticancer agents for prostate cancer cells. PLoS One, 2013, 8(9): e75601[2019-09-21]. https://doi.org/10.1371/journal.pone.0075601.  LIU Y, WANG Y, YU S, et al. The role and mechanism of CRT0066101 as an effective drug for treatment of triple-negative breast cancer. Cell Physiol Biochem,2019,52(3): 382–396. doi: 10.33594/000000027  LIU Y, LI J, MA Z, et al. Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer-related pathways in breast cancer. Cancer Med,2019,8(2): 729–741. doi: 10.1002/cam4.1938  ZOU Z, ZENG F, XU W, et al. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-kB- and HDAC1-mediated expression and activation of uPA. J Cell Sci,2012,125(20): 4800–4811. doi: 10.1242/jcs.106542  HUCK B, DUSS S, HAUSSER A, et al. Elevated protein kinase D3(PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem,2014,289(6): 3138–3147. doi: 10.1074/jbc.M113.502633  BASTEA L I, DÖPPLER H, BALOGUN B, et al. Protein kinase D1 maintains the epithelial phenotype by inducing a DNA-bound, inactive SNAI1 transcriptional repressor complex. PLoS One,2012,7(1): e30459[2019-09-21]. https://doi.org/10.1371/journal.pone.0030459. doi: 10.1371/journal.pone.0030459  RYVKIN V, RASHEL M, GADDAPARA T, et al. Opposing growth regulatory roles of protein kinase D isoforms in human keratinocytes. J Biol Chem,2015,290(17): 11199–11208. doi: 10.1074/jbc.M115.643742  MARKLUND U, LIGHTFOOT K, CANTRELL D. Intracellular location and cell context-dependent function of protein kinase D. Immunity,2003,19(4): 491–501. doi: 10.1016/S1074-7613(03)00260-7